$PLSE

Pulse Bio (PLSE) reported Q3 2026 earnings, highlighting completion of Nano-Pulse AF study enrollment ahead of schedule with 169 evaluable patients. The company has $189M in cash, supporting operations for two years. Pulse Bio's nPulse cardiac catheter system showed rapid adoption and positive feedback from physicians, with potential transformative impact. The company expects final data in Q3 2027 and CE Mark approval in Q4 2027.

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting 86% of patients evaluated achieved at least 50% nodule volume reduction at six months after a single nonthermal nsPFA treatm

Needham kept its Buy rating on Pulse Biosciences and increased its price target to $64 from $58, suggesting a 20.6% upside from the Nov 5 close of $53.07, according to the firm.

Pulse Biosciences (PLSE) reported interim results from its PRECISE-BTN study, showing 86% of patients achieved at least 50% nodule volume reduction at six months. The median volume reduction was 72%, with no serious adverse events. The company expects to report data for all patients at six and 12 months.

Mizuho raised its price target for Pulse Biosciences (PLSE) to $65 from $55, citing faster-than-expected trial progress. The stock is up 287% YTD. Q3 2026 saw a wider-than-expected loss of $0.32 per share, but revenue increased to $395,000. The company has $189.2M in cash. Analysts maintain a Strong Buy consensus with targets ranging from $55 to $80.

Pulse Biosciences (PLSE) reported a Q3 loss of $0.32 per share, beating estimates by $0.03, but missed revenue estimates by 21%. Revenue was $0.4M, up from $0.09M a year ago. The stock has gained 315.6% YTD. Future performance depends on earnings outlook and estimate revisions, with current consensus at -$0.35 EPS for Q4.

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results Completed enrollment of NANOPULSE-AF US IDE pivotal study for treatment of AF with nPulse Cardiac Catheter System Ended the quarter with $189 million of cash, cash equivalents, and ma

Pulse Biosciences (PLSE) partnered with Clayman Thyroid Center to use and study the Vybrance System for benign thyroid nodules. The center will treat patients and collect data, aiming to expand evidence and access. PLSE expects meaningful results from this collaboration.

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center Collaboration adds the nPulse ™ Vybrance ™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical data HAYWARD, Califo

Oppenheimer raised its price target for Pulse Biosciences (PLSE) to $60 from $35, citing competitor challenges. The stock trades at $52.45 with a $3.74B market cap. Analysts highlight a pivotal trial in 2027 and recent equity agreements. Multiple analysts initiated coverage with buy ratings and price targets ranging from $58 to $73.